The use of betaine for the treatment of homocystinuria

L A Smolin, N J Benevenga, S Berlow
The Journal of pediatrics 1981 99(3):467-472

Bibliography

PubMed
PMID 7264811
DOI
10.1016/s0022-3476(81)80352-6
Funding
Indexed grant support: MCT000 268 — CIT NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignIndexed case report; abstract unavailable
ModelHuman participants
SampleNot available in the indexed record
InterventionFormulation and dose require the original full report
DurationNot available in the indexed record
EndpointsHistorical or clinical context

What the study showed, in plain terms

Published in 1981, this source examined prescription betaine and inherited metabolic disorders. It is retained for source traceability. Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

The indexed record verifies the publication and citation, but supplies no abstract. A quantitative effect or complete treatment result is not established from this record alone.

Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • The indexed record verifies the publication and citation, but supplies no abstract.
  • A quantitative effect or complete treatment result is not established from this record alone.
  • The recorded outcome domains were Historical or clinical context.

What this study can and cannot tell us

  • Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.
  • Source basis: Bibliographic data only; no abstract available. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Giorgia Olivieri et al. · Journal of inherited metabolic disease · 2026
Tier 2
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency
Andrew A M Morris et al. · Journal of inherited metabolic disease · 2017
Tier 4
Postauthorization safety study of betaine anhydrous
Ulrike Mütze et al. · Journal of inherited metabolic disease · 2022
Tier 4
Cystathionine beta synthase deficiency and brain edema associated with methionine excess under betaine supplementation: Four new cases and a review of the evidence
Bernd C Schwahn et al. · JIMD reports · 2020
Tier 2
Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial
Apolline Imbard et al. · Orphanet journal of rare diseases · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology